Days at Home After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients.
Mabel ChungZaid I AlmarzooqJiaman XuYang SongSuzanne J BaronDhruv S KaziRobert W YehPublished in: Circulation. Cardiovascular quality and outcomes (2023)
In the Evolut Low Risk trial linked to Medicare, low-risk patients undergoing TAVR spend a similar number of days at home at 1 and 2 years compared with SAVR. Days spent at home at 30 and 90 days were higher in TAVR. In contrast to higher-risk patients studied in prior work, there is no clear advantage of TAVR versus SAVR for DAH in the first 2 years after AVR in low-surgical-risk patients.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- aortic valve
- aortic valve replacement
- prognostic factors
- peritoneal dialysis
- transcatheter aortic valve replacement
- magnetic resonance imaging
- patient reported outcomes
- clinical trial
- randomized controlled trial
- coronary artery disease
- study protocol
- atrial fibrillation
- health insurance